Fennec's partner Norgine launches PEDMARQSI in Germany for cisplatin-induced hearing loss prevention

FENNEC PHARMACEUTICALS INC.

PEDMARQSI (sodium thiosulfate injection) launched in Germany by Norgine for prevention of ototoxicity in pediatric patients.
First and only approved therapy in EU/UK for cisplatin-induced hearing loss in children 1 month to <18 years with localized solid tumors.
License deal (March 2024) included $43M upfront, up to $230M in milestones, and double-digit tiered royalties (mid-teens to mid-twenties).
Phase 3 data showed ~50% reduction in hearing loss vs. cisplatin alone.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.